Chapter 26: Outlook for Cancer Vaccine Development

Outlook for cancer vaccine development With the rapid incorporation of monoclonal antibodies (MAbs) into oncology therapy, an environment of acceptance of new biologic therapies – including cancer vaccines – as a viable therapeutic approach is forming. Genentech and ImClone's highly visible and successful 2004 MAb launches (bevacizumab [Avastin] and cetuximab [Erbitux], respectively) have increased anticipation for the next new therapy. Although Dendreon's long-awaited cancer vaccine, Provenge, has not yet delivered on earlier expectations, several vaccines, specifically Merck's Gardasil and GlaxoSmithKline's Cervarix, are rapidly approaching their filing dates and have the potential to initiate the therapeutic acceptance of cancer vaccines. The gold standard for cancer treatment remains chemotherapy, but combination therapy, particularly combining chemotherapy agents with biologies, is on the rise. For many biopharmaceutical companies developing cancer therapies, including those companies developing MAbs, studies of emerging treatments as monotherapies and in combination with accepted chemotherapy regimens are an important part of ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book